Abstract:Evodiamine has been a promising lead structure with broad-spectrum antitumor activity. Druggability optimization is the most challenging part of evodiamine-based lead-to-candidate campaign. Amino acids as building blocks for conjugates are widely incorporated into approved drug and drug candidates, demonstrating highly attractive druggability. Herein, a series of evodiamine amino acid conjugates were designed and synthesized based on the evodiamine lead compound (±)-8b discovered in our previous work. The structure−activity relationship (SAR) studies culminated in the identification of a promising conjugate (−)-15h featuring a N-Boc-L-glutamine group and a chiral carbon atom (sinister), which exhibited nanomolar antiproliferative activity against LoVo and RKO colorectal cancer cells. Moreover, (−)-15h could inhibit topoisomerases I, arrest the cell cycle in the G2/M phase, and induce apoptosis. Importantly, (−)-15h (tumor growth inhibition rate was 82.53% in 40 mpk) showed better efficacy and tolerability to that of parent compound (−)-8b (tumor growth inhibition rate was 51.22% in 40 mpk) in LoVo xenograft model. Further, (−)-15h (tumor growth inhibition rate was 70.09% in 40 mpk) showed comparable efficacy and better tolerability to that of topotecan (tumor growth inhibition rate was 70.67% in 0.5 mpk) in HT-29 xenograft model. Collectively, this study further provided a strong scientific basis for amino acid-based structural modifications and a drug lead for anti-colorectal cancer applications.

Discovery of Novel Triple Targeting G‑quadruplex and Topoisomerase 1/2 Ligands from Natural Products Evodiamine and Rutaecarpine

N(14)-substituted Evodiamine Derivatives As Dual Topoisomerase 1/Tubulin-Inhibiting Anti-Gastrointestinal Tumor Agents

New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives As Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations.

Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer.

Design, synthesis and bioactivity evaluation of favorable evodiamine derivative scaffold for developing cancer therapy

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Design, Synthesis and Bioactivity Evaluation of Novel N-phenyl-substituted Evodiamine Derivatives As Potent Anti-Tumor Agents

Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer

Design, Synthesis and Bioactivity Evaluation of Novel Evodiamine Derivatives with Excellent Potency Against Gastric Cancer

Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.

Design, Synthesis and Biological Evaluation of 3-Arylisoquinoline Derivatives As Topoisomerase I and II Dual Inhibitors for the Therapy of Liver Cancer.

Identification of a novel 10-hydroxyevodiamine prodrug as a potent topoisomerase inhibitor with improved aqueous solubility for treatment of hepatocellular carcinoma

Discovery of Indolo[3,2- c]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity

Structure-activity Relationship Study of Novel Evodiamine Amino Acid Conjugates with Potent Anti-Colorectal Cancer Efficacy

Two‐Phase Electrosynthesis of Dihydroxycoumestans: Discovery of a New Scaffold for Topoisomerase I poison

Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy

Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.

Novel 4β-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents

Design, synthesis and bioactivity evaluation of the combination of evodiamine and erlotinib linked by indolequinone

Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents.

Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors.